CBPO [China Biologic Products] SC 13D: (Original Filing)
[]
RENN [Renren] SC 13G/A: (Original Filing)
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
RENN [Renren] SC 13G/A: SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Commences Phase III Clinical Trials for COVID-19
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
NCTY [The9] F-1/A: (Original Filing)
[] [THE9 LIMITED CLASS A ORDINARY SHARES, PAR VALUE US$0.01 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [●], 2020 Maxim Group LLC As Representative of the several Underwriters named in Schedule I attached hereto Ladies and Gentlemen: Company Underwriters Agreement” Repr]
NCTY [The9] F-1/A:
[] [THE9 LIMITED CLASS A ORDINARY SHARES, PAR VALUE US$0.01 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [●], 2020 Maxim Group LLC As Representative of the several Underwriters named in Schedule I attached hereto Ladies and Gentlemen: Company Underwriters Agreement” Repr]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
SVA [SINOVAC BIOTECH] 6-K: Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
